Tinearest 1%
Tinearest 1% Uses, Dosage, Side Effects, Food Interaction and all others data.
Tinearest 1% is a synthetic antifungal agent that is structurally and pharmacologically related to allylamine antifungals. The exact mechanism of action has not been established, but it is suggested that butenafine's antifungal activity is exerted through the alteration of cellular membranes, which results in increased membrane permeability, and growth inhibition.
Tinearest 1% is mainly active against dermatophytes and has superior fungicidal activity against this group of fungi when compared to that of terbinafine, naftifine, tolnaftate, clotrimazole, and bifonazole. It is also active against Candida albicans and this activity is superior to that of terbinafine and naftifine. Tinearest 1% also generates low MICs for Cryptococcus neoformans and Aspergillus spp. as well.
Trade Name | Tinearest 1% |
Availability | Rx and/or OTC |
Generic | Butenafine |
Butenafine Other Names | Butenafina, Butenafine, Butenafinum |
Related Drugs | clotrimazole topical, ketoconazole topical, terbinafine, miconazole topical, Lamisil |
Type | |
Formula | C23H27N |
Weight | Average: 317.4672 Monoisotopic: 317.214349869 |
Groups | Approved |
Therapeutic Class | Topical Antifungal preparations |
Manufacturer | |
Available Country | Egypt |
Last Updated: | September 19, 2023 at 7:00 am |
![Tinearest 1% Tinearest 1%](https://www.medicinesfaq.com/media/png/tinearest-1.png)
Uses
Tinearest 1% cream is used for the topical treatment of the following superficial dermatophytosis: Interdigital tinea pedis (athlete's foot); Tinea corporis (ringworm); Tinea cruris (jock itch) due to E. floccosum, T. mentagrophytes, T. rubrum, and T. tonsurans.
Tinearest 1% is also used to associated treatment for these conditions: Pityriasis versicolor, Tinea Corporis, Tinea Cruris, Tinea Pedis
How Tinearest 1% works
Although the mechanism of action has not been fully established, it has been suggested that butenafine, like allylamines, interferes with sterol biosynthesis (especially ergosterol) by inhibiting squalene monooxygenase, an enzyme responsible for converting squalene to 2,3-oxydo squalene. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Blockage of squalene monooxygenase also leads to a subsequent accumulation of squalene. When a high concentration of squalene is reached, it is thought to have an effect of directly kill fungal cells.
Dosage
Tinearest 1% dosage
In the treatment of interdigital tinea pedis, Tinearest 1% should be applied twice daily for 7 days or once daily for 4 weeks. Patients with tinea corporis or tinea cruris should apply Tinearest 1% once daily for two weeks. Sufficient Tinearest 1% cream should be applied to cover affected areas and immediately surrounding skin of patients with interdigital tinea pedis, tinea corporis and tinea cruris.
Side Effects
Common side effects are Burning/ stinging sensation, contact dermatitis, erythema, pruritus, skin irritation.
Precaution
Tinearest 1% cream is not for ophthalmic, oral, or intravaginal use. This is for external use only. If irritation or sensitivity develops with the use of Tinearest 1% cream, treatment should be discontinued and appropriate therapy instituted.
Interaction
Potential drug interactions between butenafine HCl cream and other drugs have not been evaluated.
Food Interaction
No interactions found.Elimination Route
The total amount absorbed through the skin into the systemic circulation has not been quantified.
Half Life
Following topical application, a biphasic decline of plasma butenafine concentrations was observed with the half-lives estimated to be 35 hours initial and over 150 hours terminal.
Pregnancy & Breastfeeding use
Pregnancy Category C. As no adequate and well-controlled studies have been conducted, this drug should be used during pregnancy only if clearly needed.
Lactation: It is not known if butenafine HCl is excreted in human milk. Caution should be exercised in prescribing butenafine HCl to a nursing woman.
Contraindication
Hypersensitivity to butenafine.
Special Warning
Safety and efficacy in pediatric patients below the age of 12 years have not been studied.
Acute Overdose
Overdosage of butenafine HCl in humans has not been reported to date.
Storage Condition
Store between 5-30° C.
Innovators Monograph
You find simplified version here Tinearest 1%
Tinearest 1% contains Butenafine see full prescribing information from innovator Tinearest 1% Monograph, Tinearest 1% MSDS, Tinearest 1% FDA label